Loading clinical trials...
Loading clinical trials...
A Phase II, Randomized, Comparative, Observer-Blind, Multi-Center Study Evaluating the Safety and Immunogenicity of the Liquid Formulation of Group B Streptococcus Trivalent Vaccine and of the Lyophilized Formulation of Group B Streptococcus Trivalent Vaccine in Healthy Non-Pregnant Women Aged 18 to 40 Years
Conditions
Interventions
GBS Vaccine
GBS Vaccine
Locations
9
United States
GSK Investigational Site
Redding, California, United States
GSK Investigational Site
Lenexa, Kansas, United States
GSK Investigational Site
Baltimore, Maryland, United States
GSK Investigational Site
Stevensville, Michigan, United States
GSK Investigational Site
Salt Lake City, Utah, United States
GSK Investigational Site
Antwerp, Belgium
Start Date
November 20, 2014
Primary Completion Date
April 23, 2015
Completion Date
September 22, 2015
Last Updated
December 5, 2019
NCT07343167
NCT06473506
NCT06611371
NCT06818656
NCT04841369
NCT04258995
Lead Sponsor
GlaxoSmithKline
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions